Hemophagocytic lymphohistiocytosis (HLH) is a severe and often lethal inflammatory
syndrome characterized by excessive immune activation leading to fever, cytopenias, and …

Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint
inhibitors: case report and systematic review of the literature - PMC Back to Top Skip to …

Background: Acquired hemophagocytic lymphohistiocytosis (HLH) is a rare but potentially
fatal condition characterized by hyperactivation of macrophages and cytotoxic lymphocytes …

Background Programmed cell death protein 1 (PD-1) checkpoint inhibitors such as
pembrolizumab are novel therapeutics used to treat various advanced malignancies …

As indications for immune checkpoint inhibitors for breast cancer continue to expand, rare
toxicities will emerge that require careful consideration and multidisciplinary management …

Hemophagocytic lymphohistiocytosis (HLH) is a rare but life-threatening disorder of the
immune system. While familial HLH is usually seen in children, secondary HLH is more …

Annular lesions represent a unique macro-morphologic pattern in various skin disorders that
may be found in pityriasis rotunda, elastosis perforans serpiginosa, subacute nodular …

Objective: An association exists between immune checkpoint inhibitors and hemophagocytic
lymphohistiocytosis (HLH). Therefore, the main objective of this study was to collect data on …

The review of publications on the safety profiles of three different immunosuppressants and
immunomodulators (Alemtuzumab (ALZ), ipilimumab and nivolumab) published between …

Immune checkpoint inhibitors (ICIs) are associated with a wide range of immune-related
adverse events (irAEs). As oncological indications for ICIs widen, their rare side effects …